Quanticate appoints head of new pharmacovigilance services team

22 February 2010

Quanticate, a global biometrics clinical research organization (CRO), has appointed Dr Alison Bond to lead its new Pharmacovigilance Services team. The appointment supports Quanticate’s mission in continuing to expand its clinical trial services offerings to support customers around the world.

The new pharmacovigilance service offers clinical trial and post-marketing pharmacovigilance to provide comprehensive surveillance throughout the product lifecycle. These services include adverse event case management and reporting, signal detection and evaluation, literature screening and review, and pharmacovigilance document preparation and submission, such as Annual Safety Reports, Periodic Safety Update Reports and Risk Management Plans.

“Centralizing clinical and safety data with Quanticate creates efficiencies for our customers — hence the addition of pharmacovigilance services. This signals another exciting development for Quanticate and our customers who need to implement rigorous programs that meet regulatory requirements and protect patients,” said Quanticate’s CEO David Underwood. “Alison brings several years of experience and a depth of knowledge in this important area of drug development. Her leadership of our Pharmacovigilance Services will be of great value to our customers.”